Napp Pharmaceuticals

What Napp Pharmaceuticals does

Napp Pharmaceuticals Limited is a privately held UK pharmaceutical company headquartered at Cambridge Science Park, founded in the 1920s, with commercial operations focused on the National Health Service. The company develops, markets and distributes branded prescription medicines across four therapeutic areas: pain management (opioid analgesics including OxyContin, MST Continus, Palladone, BuTrans and Targinact, plus the overdose reversal product Nyxoid), respiratory medicine (flutiform pressurised metered-dose inhaler for asthma), cardiovascular medicine (Adizem diltiazem products), and infectious disease (REZZAYO/rezafungin, the first new invasive candidiasis treatment authorised in Great Britain in over 15 years, MHRA-approved February 2024). Napp also operates oncology support products including Pelmeg (pegfilgrastim).

The company's group structure comprises three UK-registered private limited companies: Napp Pharmaceutical Holdings Limited as parent, Napp Pharmaceuticals Limited as primary commercial entity, and two wholly owned subsidiaries — Bard Pharmaceuticals Limited (manufacturing and supply chain, exporting to over 40 countries) and Qdem Pharmaceuticals Ltd (branded generic medicines to the NHS). Napp holds commercial rights in Great Britain for rezafungin via a licensing arrangement with Cidara Therapeutics and Mundipharma, and collaborates with Vectura on flutiform pMDI reformulation.

The business model is sales-led and centred on UK NHS procurement channels, with enterprise field sales targeting physicians, pharmacists and commissioners in primary and secondary care, joint working partnerships with NHS stakeholders spanning approximately 30 years, and medical education delivered through Napp Academy. Pricing follows standard UK NHS unit pricing across the branded portfolio. The company operates within the global Mundipharma network of independent associated companies, with leadership comprising CEO Charles Graffi, Group Finance Director Will Johnson and Managing Director Hywel Day. Headcount at Napp is in the 251-500 range, while the broader Mundipharma network employed over 2,600 people as of 2022.

Name

Napp Pharmaceuticals

Legal name

Napp Pharmaceuticals Limited

Website

https://napp.co.uk

Company type

Private

Founded year

1920

Operating status

Operating

Headcount range

251–500 employees

Short description

Napp Pharmaceuticals is a privately held UK pharmaceutical company, headquartered in Cambridge, that develops and markets branded prescription medicines in pain management, respiratory, cardiovascular and infectious disease for the National Health Service, operating through wholly owned subsidiaries Bard Pharmaceuticals (manufacturing) and Qdem (branded generics).

Ownership category

akta.pro rank

Product category

Branded Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Branded pharmaceutical products
• Pain management medicines
• Respiratory inhalers
• Antifungal therapeutics
• Branded generic medicines

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Branded Pharmaceutical Sales: Sale of proprietary branded medicines to the NHS including pain management products (OxyContin, MST Continus, Palladone, BuTrans, Targinact), respiratory products (flutiform), and specialty pharmaceuticals. Revenue generated through NHS procurement channels.
2. Branded Generic Medicines (Qdem): Qdem Pharmaceuticals, wholly owned subsidiary, provides branded generic medicines to the NHS including Butec (buprenorphine patches), Longtec and Shortec (oxycodone products). Revenue through NHS pricing and reimbursement.
3. Licensing Royalties (Rezafungin): Rezafungin developed by Cidara Therapeutics with Mundipharma holding commercial rights outside US and Japan. Napp supplies rezafungin in Great Britain under licensing arrangement.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Napp Pharmaceuticals develops, manufactures, and commercialises branded pharmaceutical medicines for the UK NHS across four therapeutic areas: pain management (opioid analgesics including morphine, oxycodone, hydromorphone, buprenorphine, and naloxone formulations), respiratory medicine (flutiform inhaler for asthma), cardiovascular medicine (diltiazem products), and infectious disease (rezafungin/REZZAYO for invasive candidiasis). Through its Qdem subsidiary it also supplies branded generic medicines, and via Bard Pharmaceuticals handles manufacturing and international export to over 40 countries.

Product overview

Napp Pharmaceuticals operates as a UK-focused commercial pharmaceutical company with a diverse portfolio of branded medicines. The portfolio centers on four main therapeutic areas: pain management (opioid analgesics including morphine, oxycodone, hydromorphone, buprenorphine, and naloxone products), respiratory medicine (flutiform inhaler for asthma), cardiovascular medicine (diltiazem products), and infectious disease (rezafungin for invasive candidiasis). The company also operates through its Qdem Pharmaceuticals subsidiary offering branded generic medicines. Products span multiple formulations including tablets, capsules, injections, transdermal patches, nasal sprays, and inhalers. Bard Pharmaceuticals Limited handles manufacturing and supply chain operations.

Differentiator

Problem solved

Functional benefit

Brands

• QDEM: Branded generic medicines brand operated by subsidiary Qdem Pharmaceuticals Ltd, providing generic versions of medicines to the NHS.

Products and services

• OxyContin tablets Oxycodone hydrochloride controlled-release tablets for pain management, available in 5mg to 120mg strengths, supplied to UK NHS.
• MST Continus tablets Morphine sulfate sustained-release tablets for chronic pain management, available in 5mg to 200mg strengths.
• MXL capsules Morphine sulfate extended-release capsules for chronic pain, available in 30mg to 200mg strengths.
• Sevredol tablets Morphine sulfate immediate-release tablets for acute severe pain, available in 10mg, 20mg, and 50mg strengths.
• Palladone capsules (immediate-release) Hydromorphone hydrochloride immediate-release capsules for severe pain, available in 1.3mg and 2.6mg strengths.
• Palladone SR capsules Hydromorphone hydrochloride sustained-release capsules for severe pain management, available in 2mg to 24mg strengths.
• Palladone injection Hydromorphone hydrochloride injection for severe pain management, available in 2mg/ml and 10mg/ml concentrations.
• BuTrans patches Transdermal buprenorphine patches for pain management, available in 5, 10, 15, and 20 mcg/hr strengths.
• Targinact tablets Oxycodone hydrochloride and naloxone hydrochloride combination tablets for chronic pain with reduced opioid-induced constipation risk, available in 5/2.5mg to 40/20mg strengths.
• OxyNorm capsules Oxycodone hydrochloride immediate-release capsules for pain, available in 5mg, 10mg, and 20mg strengths.
• OxyNorm injection Oxycodone hydrochloride injection for acute pain management, available in 10mg/ml and 50mg/ml concentrations.
• OxyNorm liquid and concentrate Oxycodone oral solution for pain management, available as oral concentrate 10mg/ml and oral liquid 1mg/ml.
• Nyxoid nasal spray Naloxone hydrochloride nasal spray for emergency treatment of opioid overdose.
• flutiform inhaler Pressurised metered-dose inhaler containing fluticasone propionate and formoterol fumarate for asthma treatment, available in 50/5mg, 125/5mg, and 250/10mg strengths. Currently being reformulated with environmentally friendly propellant.
• Adizem-SR capsules Sustained-release diltiazem hydrochloride capsules for cardiovascular conditions, available in 90mg, 120mg, and 180mg strengths.
• Adizem-XL capsules Extended-release diltiazem hydrochloride capsules for cardiovascular conditions, available in 120mg to 300mg strengths.
• Pelmeg injection Pegfilgrastim injection for reducing neutropenia in chemotherapy patients.
• REZZAYO (rezafungin) Rezafungin acetate powder for concentrate for solution for infusion; novel once-weekly echinocandin antifungal authorised for treatment of invasive candidiasis in adults in Great Britain. First new treatment option in over 15 years for eligible adult patients.
• Butec patches (Qdem) Buprenorphine transdermal patches from Qdem Pharmaceuticals subsidiary for pain management, available in 5, 10, 15, and 20 microgram/hour strengths.
• Longtec (Qdem) Oxycodone hydrochloride prolonged-release tablets from Qdem Pharmaceuticals subsidiary, available in 5mg to 120mg strengths.
• Shortec (Qdem) Oxycodone hydrochloride hard capsules and injection from Qdem Pharmaceuticals subsidiary, available as 5mg to 20mg hard capsules and 10mg/ml to 50mg/ml injection solutions.

Quantifiable outcome

• First new treatment option in over 15 years for invasive candidiasis with rezafungin (REZZAYO)
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• VecturaflagshipStrategic or Co-development Partner · 16 April 2024Collaboration agreement to reformulate flutiform pressurised metered-dose inhaler (pMDI) with environmentally friendly propellant. Vectura provides expertise in inhalation contract development and manufacturing. Goal is near-zero-emissions product aligned with EU fluorinated greenhouse gas regulations.
• MundipharmacoreStrategic or Co-development PartnerNapp is part of the global network of Mundipharma independent associated companies. Mundipharma has presence across Africa, Asia Pacific, Canada, Europe, Latin America, and Middle East. Mundipharma is dedicated to bringing innovative treatments in respiratory, pain management, infectious disease and consumer healthcare.
• Bard Pharmaceuticals LimitedcoreStrategic or Co-development PartnerBard Pharmaceuticals Limited is a Cambridge-based production and supply chain company and wholly owned subsidiary of Napp Pharmaceutical Holdings Limited. It manufactures and exports medicines to over 40 countries worldwide.
• Qdem Pharmaceuticals LtdcoreStrategic or Co-development PartnerQdem Pharmaceuticals Ltd is a wholly owned subsidiary of Napp Pharmaceuticals Limited providing branded generic medicines to the NHS. Located at Cambridge Science Park.
• NHS (UK National Health Service)flagshipStrategic or Co-development PartnerNapp's longest standing partnership is with the NHS working since its inception. Joint Working arrangements pool skills, experience and resources for joint development and implementation of patient-centred projects. Works with NHS policy makers, clinicians, commissioners at national and local levels.
• Healthcare ProfessionalscoreStrategic or Co-development PartnerNapp works in partnership with healthcare professionals for the benefit of patients. Partnerships include advising on medicines, speaking at meetings, supporting attendance at conferences and continued development. All transfers of value declared annually under ABPI Code of Practice.
• Vectura Fertin PharmacoreStrategic or Co-development PartnerParent company of Vectura, a specialist inhalation contract development and manufacturing organization (CDMO) providing inhaled drug development solutions.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Endo International: Specialty pharmaceutical company with branded pain portfolio including opioid analgesics and specialty sterile injectables. Comparable as a pain-focused specialty pharma with overlapping molecules and similar commercial dynamics around opioid prescribing.
• Grünenthal: German privately-held pharmaceutical company specializing in pain management with a portfolio including opioids and innovative pain therapies. Comparable as a mid-sized, privately-owned, pain-focused specialty pharma with branded opioid franchise similar to Napp.
• Indivior: UK-headquartered specialty pharmaceutical company focused on opioid dependence and addiction treatment. Directly comparable as a UK-based specialty pharma with opioid-related expertise and NHS commercial focus, addressing adjacent patient populations to Napp's opioid pain portfolio.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company historically focused on pain management including branded opioid analgesics and hospital specialty products. Comparable as a pain-management focused specialty pharma with overlapping molecule exposure (oxycodone, morphine) and hospital-channel distribution.
• Hikma Pharmaceuticals: UK-headquartered, publicly-listed specialty pharmaceutical company with branded and generic operations across pain, respiratory, and other therapeutic areas. Comparable as a UK-rooted, mid-sized specialty pharma serving NHS and global markets with similar product categories.
• Chiesi Farmaceutici: Italian privately-held pharmaceutical company with significant respiratory franchise including pMDI and dry powder inhalers. Directly comparable on the respiratory side through Chiesi's investments in low-carbon propellant transitions and similar patient populations to flutiform.
• Vectura Group: UK inhalation contract development and manufacturing organization (CDMO) and former specialty pharma, now part of Vectura Fertin Pharma. Direct peer and active commercial partner through the flutiform pMDI reformulation agreement with comparable inhalation expertise.
• Mundipharma: Parent global network of independent associated companies covering pain management, respiratory, infectious disease, and consumer healthcare across multiple continents. Mundipharma is the parent and operating counterpart of Napp with overlapping therapeutic areas and pipeline assets.

Broad incumbents

• Cipla: Indian-headquartered global pharmaceutical company with respiratory and specialty pharma operations across 80+ countries. Comparable as a broader incumbent with respiratory franchise (including pMDIs) and chronic pain products, providing context on global competitive dynamics.

Regional players

• Aspen Pharmacare: South African-headquartered specialty pharmaceutical company with significant presence in UK and other emerging markets through branded and generic portfolios including anaesthetics and pain products. Comparable as a privately-held specialty pharma with UK operations and similar therapeutic focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/napp-pharmaceuticals

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Napp Pharmaceuticals